The dual targeting of immunosuppressive cells and oxidants promotes effector and memory T-cell functions against lung cancer.
We have recently demonstrated that the combination of gemcitabine and a superoxide dismutase mimetic protects mice against lung cancer by suppressing the functions of myeloid-derived suppressor cells and by activating memory CD8+T-cell responses. Persistent memory cells exhibited a glycolytic metabolism, which may have directly enhanced their effector functions. This combinatorial therapeutic regimen may reduce the propensity of some cancer patients to relapse.
Department of Pathology; The University of Alabama at Birmingham; Birmingham, AL USA.
Anandi
A
Sawant
Department of Medicine; The University of Alabama at Birmingham; Birmingham, AL USA.
Cara C
CC
Schafer
Department of Pathology; The University of Alabama at Birmingham; Birmingham, AL USA.
Selvarangan
S
Ponnazhagan
Department of Medicine; The University of Alabama at Birmingham; Birmingham, AL USA.
Jessy S
JS
Deshane
antitumor immunity; combination therapy; lung cancer; memory response; metabolism; myeloid-derived suppressor cells; oxidative stress